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Summary 
Survival outcomes for adolescent and young adult patients with soft tissue sarcomas lag behind 
those of children diagnosed with histologically similar tumours. To help understand these 
differences in outcomes, we discuss the following issues with regard to the management of 
these patients with soft tissue sarcomas: delays in diagnosis, trial availability and participation, 
aspects of the organisation of care (with an emphasis on age-specific needs), national 
centralisation of sarcoma care, international consortia, and factors related to tumour biology. 
Improved understanding of the causes of the survival gap between adolescents and young 
adults with sarcomas will help drive new initiatives to improve final health outcomes in these 
populations. In this Review, we specifically focus on embryonal and alveolar 
rhabdomyosarcoma, synovial sarcoma, and adult soft tissue sarcomas diagnosed in adolescents 
and young adults, and discuss the age-specific needs of these patients. 
  
Introduction 
Sarcomas are rare tumours of connective tissue characterised by marked heterogeneity and 
including more than 70 histological subtypes.1 Sarcomas are rare, representing 6–15% of 
paediatric cancers (<15 years), 11% of adolescent and young adult cancers (15–29 years), and 
1–2% of adult cancers worldwide.2–4 In children aged 0–15 years, the largest group of soft 
tissue sarcomas consists of rhabdomyosarcoma, where osteosarcoma or Ewing's sarcoma are 
the most prevalent bone tumours.4 Rhabdomyosarcoma occurs mainly in children younger than 
7 years, with another incidence peak during adolescence (16–19 years). The peak incidence of 
osteosarcoma in children coincides with the growth spurt during adolescence, with a second 
peak in older adults (>80 years), in whom the disease is much less common. Osteosarcoma in 
elderly people is most often localised to the head and neck region, or it can be associated with 
irradiation or Paget's disease of the bone. Ewing's sarcoma, which can occur in bones and soft 
tissue, also occurs predominantly in children and young adults, and similarly has a peak age of 
incidence in adolescents, but with no second peak in older adults. Synovial sarcoma, a soft 
tissue sarcoma, has a peak incidence in individuals in their early to mid 30s, but can occur in 
children (aged 1–18 years). For patients younger than 18 years with soft tissue sarcoma other 
than rhabdomyosarcoma or synovial sarcoma, the fact that there is little connection with the 
adult sarcoma community and inadequate access to novel drugs hampers progress in improving 
survival for this population. 
Paediatric sarcomas, including embryonal and alveolar rhabdomyosarcoma, Ewing's sarcoma, 
and osteosarcoma, are characterised by their chemosensitivity and the fact that chemotherapy 
is an integral part of the treatment programme for patients of all ages, which has largely been 
responsible for the improvements in survival seen over the past 30 years. However, this 
development has been less pronounced for other soft tissue sarcomas occurring at a young age, 
such as synovial sarcoma, and it is certainly not true for malignant peripheral nerve sheath 
tumours and alveolar soft part sarcoma. 
It has been known for many years that the prognosis of sarcomas varies with age, being 
substantially superior in children compared with young adults; although the reasons for this 
discrepancy are not fully clear, they are multifactorial.5 Because the centralisation of care 
occurred much earlier for children with cancer than for adults, most children with sarcoma are 
treated according to standard protocols or within clinical studies. By contrast, the care of young 
adults with soft tissue sarcomas is still considerably disparate in many countries. Adherence to 
treatment protocols (as exemplified in patients with acute lymphoblastic leukaemia), treatment 
dose intensity, and treatment in expert paediatric centres could explain both the improvement 
in outcome for childhood sarcomas in recent decades and the differences in outcome between 
children and young adults with histologically similar sarcomas.6–10 To understand the 
differences between outcomes in adolescents and young adults and those in children and adults, 
various other factors need to be taken into consideration. 
A higher stage at diagnosis is often reported to contribute to worse outcomes. Adolescents and 
young adults tend to present with symptoms at a more advanced stage than do children, and 
this delay in diagnosis could influence outcomes, at least in certain tumours.11,12 This relation 
between delay in diagnosis and survival is, however, complex, and is partly due to patient-
related factors and partly due to physician-related or health-system-related factors. Moreover, 
in some diseases, the biology of the tumour is so dominant that it overrules any effect that delay 
in diagnosis from these above-mentioned factors could have on survival. 
The shortage of available trials and poor accrual to existing trials have also been identified as 
important factors contributing to the worse survival of adolescents and young adults with 
sarcomas compared with children. Accrual of adolescent and young adult patients with soft 
tissue sarcomas has been reported to be about 5–34% of the expected accrual based on 
incidence, compared with more than 70–80% for paediatric patients.13 This issue was 
exemplified in an analysis by the European paediatric Soft Tissue Sarcoma Study Group 
(EpSSG) that allowed patients aged up to 21 years to be included in the study. The study 
showed an observed accrual rate for EpSSG trials of 64% for patients aged 0–14 years 
compared with 30% for patients aged 15–19 years.14 The so-called five As model (availability, 
accessibility, awareness, appropriateness, and acceptability) has been proposed in a bid to 
improve participation of adolescents and young adults in clinical trials.15 
Although the impact of treatment on outcomes is often mentioned, we must not ignore the 
contribution of patient-related factors. Adolescents and young adults with cancer face specific 
problems. Care for, and treatment of, adolescents and young adults in general is a largely new 
discipline in oncology.16–18 At a global level, organisation of this care is very sparse and many 
initiatives are still in early stages. These patients are in a developmental phase of their life when 
they are suddenly confronted with a life-threatening disease. While their siblings and friends 
learn how to live independently, young people with cancer often face stagnation or even 
regression in their own personal development. These factors have a role—albeit not necessarily 
a well defined one—in adherence to treatment, and thus in final outcomes. Although these 
aspects have not yet been studied in detail for adolescents and young adults with sarcoma, there 
is no reason to assume that they will not be applicable to these patients. 
When considering differences in outcome between children and adolescents and young adults 
with soft tissue sarcomas, differences in the biology of the tumour should also be taken into 
account. Many aspects of sarcoma biology are not fully clear at this stage, but the best known 
example of the correlation between age-related biological factors and worse outcomes can be 
found in synovial sarcoma.19 Increased genomic complexity with increasing age might at least 
partly explain good survival outcomes for children.20 
In this Review, we focus on soft tissue sarcomas of adolescence and young adulthood, and 
exemplify the different features of the most prevalent soft tissue sarcomas that are either typical 
paediatric ones and occur at childhood, adolescence, and young adulthood, or that typically 
occur predominantly during adolescence and young adulthood; we also focus on adult-type soft 
tissue sarcomas that are present in paediatric, adolescent, and young adult patients. By doing 
so, we aim to explore the different factors that might explain why adolescent and young adult 
patients with soft tissue sarcomas have worse outcomes than do children. We focus on soft 
tissue sarcomas, with the exception of gastrointestinal stromal tumours, which are very rare in 
children and adolescents and are distinct from gastrointestinal stromal tumours in adults with 
regards to sex (occurring more frequently in women than in men), presentation (mainly gastric 
and multifocal), mutation status (mostly caused by an absence of activating mutations: 85% in 
paediatric gastrointestinal stromal tumours vs 15% in adult gastrointestinal stromal tumours), 
and response to imatinib.21 
 
Rhabdomyosarcoma 
Management of rhabdomyosarcoma in adolescents and young adults can be challenging. 
Among the different soft tissue sarcoma histotypes, rhabdomyosarcomas represent a distinct 
entity that clearly differs from other soft tissue sarcomas with regard to its natural history and 
sensitivity to chemotherapy. Rhabdomyosarcomas are always characterised by a high grade of 
malignancy and a marked propensity to metastasise, such that all patients with 
rhabdomyosarcoma are assumed to have micrometastatic disease at diagnosis and therefore 
need to be treated with systemic therapy. Conversely, rhabdomyosarcomas are generally 
characterised as having a good response to chemotherapy, with responses of roughly 80–
90%,22–26 as well as good responses to radiotherapy in general. 
Embryonal and alveolar rhabdomyosarcomas typically occur in children (accounting for more 
than 50% of soft tissue sarcomas in paediatric patients) but they can also occur in adults, albeit 
rarely. In contrast to the classical histological classification, a biological characterisation might 
be more accurate for predicting prognosis, and this form of classification is currently being 
incorporated in risk stratification. Patients are classified as having either fusion-negative 
rhabdomyosarcomas (corresponding to embryonal rhabdomyosarcoma) or PAX3–FOXO1 or 
PAX7–FOXO1 fusion-positive rhabdomyosarcomas (ie, alveolar rhabdomyosarcoma). Fusion-
negative rhabdomyosarcomas with an alveolar histological appearance have a genomic profile 
and a clinical course more similar to embryonal rhabdomyosarcomas than to fusion-positive 
alveolar cases.27,28 In adults, the predominant rhabdomyosarcoma subtype is pleomorphic, 
which should be considered as a separate type of rhabdomyosarcoma because it behaves like 
other high-grade soft tissue sarcomas of adulthood and does not have the same 
chemosensitivity associated with embryonal and alveolar rhabdomyosarcomas. In this Review, 
we focus on paediatric types of rhabdomyosarcomas—namely, the embryonal and alveolar 
subtypes. 
The gain in survival achieved in children with rhabdomyosarcomas in the past few decades 
(approximately 70% of patients with localised disease can now be cured24,25) has been ascribed 
to the centralisation of care in specialised centres and the high rate of inclusion in cooperative 
multi-institutional clinical trials that are able to enrol a large number of patients on the basis of 
a risk-adapted, intensive multimodal treatment strategy.8,10,22–25,29 
Although optimal local treatment remains an essential part of the treatment programme of 
rhabdomyosarcomas, multi-agent chemotherapy can be considered the mainstay of therapy. 
This is an important distinction between paediatric and adult soft tissue sarcomas. The 
chemosensitivity of rhabdomyosarcoma has altered the role of local therapies, leading to an 
increased use of conservative organ-sparing surgery and a reduction in the proportion of 
patients for whom radiotherapy is indicated (or the doses used), to minimise, when possible, 
the risk of long-term radiation-related sequelae.30 The backbone of treatment for paediatric 
patients with localised rhabdomyosarcoma is an intensive alkylation-based multidrug 
chemotherapy regimen given for 6–9 months: ie, the IVA (ifosfamide, vincristine, 
dactinomycin) regimen or the VAC (vincristine, dactinomycin, cyclophosphamide) 
regimen.24,31 Doxorubicin has been investigated as being an effective drug, but results from an 
EpSSG study32 show that addition of doxorubicin to the standard IVA regimen did not improve 
outcomes in the localised high-risk population. The addition of irinotecan-vincristine to VAC 
in the ARST0531 study33 did not improve outcomes compared with the standard arm, but since 
irinotecan-vincristine plus VAC showed less toxicity (due to less alkylating agents) than the 
standard VAC regimen it has become the current standard for the Children's Oncology Group. 
Additional treatment options for rhabdomyosarcoma include low-dose metronomic 
chemotherapy maintenance (under investigation in Europe),26,34 the dose-compression 
approach (full-dose chemotherapy administered with a shorter interval between doses; eg, 1–2 
weeks instead of the usual 3 weeks) that proved to be effective in patients with metastatic 
disease whose outcomes are generally poor (ClinicalTrials.gov number: NCT00354744),35 and 
potentially effective targeted agents (eg, temsirolimus, such as in NCT02567435).26 
The prognosis of rhabdomyosarcoma depends on multiple factors, including histological 
subtype, primary tumour site and size, lymph node involvement, and distant metastasis. 
Complex risk stratification based on these variables is used in paediatric cancer trial protocols 
to determine the appropriate intensity of treatment.36,37 Among these variables, the patient's age 
has also emerged as a factor that substantially influences survival: in various series,38,39 patients 
over 10 years of age have been reported to have a worse prognosis than children younger than 
10 years of age. In an Italian study that compared clinical features of adolescents (aged 15–19 
years) with those of children (<15 years) treated with the same therapeutic strategies,40 the 
adolescent subgroup was shown to have a significantly higher prevalence of unfavourable 
features (including the alveolar subtype, nodal infiltration, and metastases at diagnosis) than 
those prevalent in children, a significant delay in diagnosis (confirmed by other studies), a 
reduced likelihood of being enrolled in the national cooperative paediatric treatment protocol 
(27% for adolescents vs 90% for children), and worse survival (5-year overall survival of 
57·2% in patients aged 15–19 years vs 68·9% in patients <15 years; p<0·006). 
The clinical characteristics and outcomes appeared to be even more unfavourable in adults with 
rhabdomyosarcomas than in adolescents. The few published series on adult patients described 
poor outcomes, with overall survival in the range of 20–50%.41–43 An epidemiological 
analysis44 from the North American Surveillance, Epidemiology and End Results (SEER) 
database, comparing 1071 adults (>19 years) with 1529 children (≤19 years), confirmed that 
adults were more likely than children to have adverse prognostic variables. However, the final 
outcome (a 5-year survival rate of 26·6% in adults vs 60·5% in children) appeared to be 
independent of these variables, because adults had significantly worse treatment outcomes 
when a subset of patients with similar tumours was compared (ie, with the same histotype, 
same stage, and same sites).44 The EUROCARE-5 study5 reported 5-year survival rates of 
66·6% among patients aged 0–14 years with rhabdomyosarcomas diagnosed between 2000 and 
2007, compared with 39·6% among patients aged 15–19 years during the same period. 
No explanation is available for the fact that outcomes worsen with increasing age. Inadequate 
experience among adult oncologists for the treatment of non-pleomorphic rhabdomyosarcomas 
is likely to have a role. Management of embryonal and alveolar rhabdomyosarcomas in adults 
is compromised by inadequate care in specialised centres in some countries, resulting in 
patients being treated at several sites by non-specialists who only occasionally encounter 
patients with these tumours. Likewise, there is a scarcity of dedicated treatment protocols for 
adolescents and young adults. The delivery of treatment might therefore have an important 
role.29 A large, retrospective, single-institution study43 stratified adult patients with embryonal 
and alveolar rhabdomyosarcoma according to the degree to which they had been treated 
appropriately, on the basis of existing treatment guidelines for childhood rhabdomyosarcoma. 
The study confirmed poor overall results in adults (a 5-year survival of 40%), with only 43 
(39%) of 110 patients treated in line with paediatric treatment protocols. For this 39%, the 
outcome was similar to that of paediatric patients (ie, 5-year survival in this subgroup was 61% 
and increased to 72% for patients with embryonal rhabdomyosarcomas), and overall rate of 
response to chemotherapy was 85%.43 These findings suggest that adult patients would fare 
better if they were treated with properly administered paediatric regimens.44 
The factors that prevent adult patients from receiving proper treatment need to be clarified. 
Various studies45–48 have described differences in pharmacokinetics—for example, in the 
metabolism of vincristine, dactinomycin, and alkylating agents—in relation to age that might 
be responsible for different responses and toxicity. In other words, treatment protocols 
designed for children might be less effective or too toxic for adult patients. However, an 
extensive discussion of age-related pharmacological aspects to explain the differences in 
toxicity related to different chemotherapeutic drugs is beyond the scope of this Review. New 
strategies of cooperation and collaboration between paediatric and adult oncologists are clearly 
needed for adult patients with rhabdomyosarcomas. Paediatric cooperative groups have raised 
the upper age limits for their protocols (up to 25 years in Europe32 and up to 50 years in the 
USA33), but adult oncologists need to be involved in the development of these studies from the 
outset. The Italian Sarcoma Group, which is mainly concerned with adult oncology, has 
developed a prospective registry for adult patients with rhabdomyosarcoma, with some 
treatment suggestions based on paediatric strategies in cooperation with paediatric experts. An 
assessment of the results of this initiative is ongoing. 
Little information is available on the biology of paediatric-type rhabdomyosarcoma in adults; 
a more pronounced expression of multidrug-resistant proteins in these tumours has been 
described in adults than in paediatric counterparts,49 but further collaborative efforts are needed 
to increase our knowledge of rhabdomyosarcoma biology in adults and, if differences are 
found, to adjust the treatment strategy accordingly. 
 
Synovial sarcoma 
Few studies have directly compared overall outcomes of adults and adolescents with synovial 
sarcoma in the same setting, but those that have compared these groups showed that younger 
patients with synovial sarcoma have a better outcome than do older patients (table),19,50–53 with 
the exception of a retrospective series51 of 250 patients. In a large analysis50 of 213 children 
and adolescents (<18 years) and 1055 adults (≥19 years), based on data from the SEER 
database, survival was improved in young patients, with a 5-year cancer-specific survival of 
83% (SD 79·9–86·1) for children and adolescents compared with 62% (SD 60·2–63·8) for 
adults (p<0·001). This difference was particularly important for patients older than 30 years 
compared with patients younger than 18 years (hazard ratio [HR] 3·36; 95% CI 2·05–5·39; 
p<0·001). In this study, children and adults had a similar stage at presentation, but different 
outcomes. A nationwide study19 based on data from the Netherlands Cancer Registry included 
613 patients, of whom 461 had localised disease. The 5-year overall survival (calculated on the 
basis of Kaplan-Meier curves) of patients with localised disease decreased with age: 89·3% 
(SD 84·7–93·9) in children younger than 18 years, 73·0% (SD 69·2–76·8) in patients aged 18–
34 years; 54·7% (SD 51·1–58·3) in patients aged 35–65 years, and 43·0% (SD 36·0–50·0) in 
patients over 65 years of age.19 Relative survival rates, used as a proxy for disease-specific 
survival, were not largely different from estimated overall survival rates, except for patients 
over 65 years for whom relative survival was 52% at 5 years and 46% at 10 years. Treatment 
effects were not observed in this localised group. Apart from age, the site and size of the tumour 
had a significant impact on survival. In a retrospective study52 of 237 patients aged 15–35 years 
with localised synovial sarcoma, age was strongly associated with outcome, with worse 
outcomes for patients older than 35 years in univariate and multivariate analyses, both for 
overall survival (HR 2·16; p=0·004) and for distant recurrence-free survival (HR 1·56; 
p=0·028). Finally, the results of Ferrari and colleagues,53 based on a single-centre retrospective 
analysis, show a decrease in metastasis-free survival with increasing age (table). The precise 
reasons for these differences were, until recently, not well understood. For synovial sarcoma, 
there are no conclusive data to show that early tumour detection has age-related aspects, or to 
prove that early detection is associated with favourable outcomes.  
New data on molecular profiling in synovial sarcoma have revealed interesting insights. To 
analyse the intrinsic molecular behaviour of synovial sarcoma, a 67-gene signature related to 
chromosome integrity and genomic complexity named CINSARC (a complexity index in 
sarcoma) has been developed, along with a genomic index that uses comparative genomic 
hybridisation on tumour cells (figure). These indices have shown high prognostic value in adult 
soft tissue sarcomas.20,54 A subsequent analysis20 comparing 100 adult and paediatric synovial 
sarcoma specimens confirmed that a somatic genomic complexity analysis can predict tumour 
outcomes for this disease. Even if tumours in the two groups shared the same histological 
features, translocations, and types of fusion transcripts, they had completely different 
metastatic outcomes. No specific gene patterns were found to discriminate between paediatric 
and adult tumours, but a strong link was observed between the degree of genomic complexity 
and the metastatic outcome in children.20 Specifically, paediatric patients with tumours that 
had no detectable quantitative rearrangements did not develop metastases. However, for adults, 
37 (64%) of 58 patients harboured rearrangement profiles, of whom 28 (76%) developed 
metastases, compared with 4 (19%) of 21 paediatric patients. This study offers a biological 
explanation for the widely differing outcomes of paediatric and adult patients with synovial 
sarcomas, showing that metastatic outcomes are strongly associated with chromosomal 
complexity in both age groups and that this instability is frequent in adult synovial sarcomas 
but not in paediatric synovial sarcomas.20 This prospective clinical validation of the genomic 
index in synovial sarcomas confirms that this index is an important molecular prognostic 
marker that is easy to use and has the potential to guide therapeutic management. An open 
study in synovial sarcoma, called Synobio, on paediatric patients (aged 0–25 years) from the 
EpSSG, aims to confirm the prognostic value of the genomic index. 
In addition to the stage at diagnosis and molecular profile, age-related differences between 
children and young adults might exist in the application of chemotherapeutic regimens for 
patients with synovial sarcomas. Lagarde and colleagues20 have suggested that greater use of 
chemotherapy in paediatric patients (≤18 years) than in adults (>19 years) might explain the 
differences in survival (81·8% of children receiving chemotherapy vs 41·7% of adults). 
However, such a treatment effect was not seen in the study19 from the Netherlands Cancer 
Registry, in which adjuvant chemotherapy had no effect on survival. To date, neoadjuvant 
chemotherapy in adult patients (aged >18 years) with synovial sarcoma has not shown a 
survival benefit in published studies.52,55 The question of whether response to chemotherapy 
might be related to genomic complexity may arise. However, a study by Chabika and 
colleagues56 showed no association between these two variables. Therefore, the mechanism 
leading to metastatic relapse of synovial sarcoma is likely to be an intrinsic biological 
characteristic of the tumour rather than one related to its specific sensitivity to chemotherapy. 
Nevertheless, disparities in access to specialised care and enrolment in clinical trials might also 
explain some of the differences in survival, as the adolescent and young adult populations are 
not commonly included in treatment protocols.17 
 
Adult soft tissue sarcomas in paediatric and adolescent 
patients 
The majority of soft tissue sarcoma histologies collectively termed non-rhabdomyosarcoma 
soft tissue sarcomas by paediatric oncologists are those that occur in adulthood.57–61 The term 
non-rhabdomyosarcoma soft tissue sarcomas, still used by paediatric oncologists, reflects the 
historical approach to treatment according to the principles derived from the management of 
rhabdomyosarcoma, which is clearly a distinct entity. However, during the past few decades, 
both the European and the North American paediatric cooperative groups have developed 
clinical protocols specifically tailored to these tumours, with an effort to adapt their treatment 
approach so that it resembles that used for adults.62 Current paediatric treatment programmes 
use the same variables for risk stratification known to influence survival in adults and adopt 
the full-dose ifosfamide-doxorubicin regimen as standard chemotherapy when systemic 
treatment is required.63–67 However, the distribution of soft tissue sarcoma subtypes differs 
considerably between adults and children, and various data suggest that the clinical behaviour 
of a given histology might be different in different age groups, with the clinical course of 
paediatric tumours generally being more favourable than that of adult tumours, but head-to-
head comparisons in similar patients groups with soft tissue sarcomas are scarce. Although the 
decline in age-related outcomes occurs gradually, synovial sarcoma is an exception: children 
have a notably better outcome than do adults.67,68 Therefore, caution should be taken in 
extrapolating data from adult series and in applying adult treatment protocols to children (eg, 
the indication for radiotherapy could vary according to the age of the patient, because of the 
different degrees of risk and the potential impact of radiation-induced sequelae). 
Clinical management of adolescents and young adults with soft tissue sarcomas is a challenge, 
requiring an experienced multidisciplinary team with specific skills. Referral to high-volume 
centres and adherence to treatment guidelines have been reported to be important factors 
associated with improved survival for this patient population.69–71 
The complexity of the treatment of soft tissue sarcomas is also related to their biological 
heterogeneity according to tumour grade and histological subtype. Although surgery is the 
keystone of treatment, the responsiveness of adult soft tissue sarcomas to chemotherapy is 
generally uncertain. However, the heterogeneity of soft tissue sarcomas also affects the 
predictability of response to chemotherapy; for example, synovial sarcoma is more sensitive to 
standard chemotherapy than are other soft tissue sarcomas such as alveolar soft-part sarcoma 
or clear cell sarcoma. 
Neoadjuvant chemotherapy in patients with unresectable advanced disease might achieve 
tumour shrinkage and convert unresectable cancers into conservative complete resections, as 
well as helping to treat any micrometastases promptly, because these patients are at a high risk 
of distant dissemination regardless of the local control measures adopted. Reported responses 
to chemotherapy were slightly higher in a paediatric series than in adults, with a variability 
related to tumour grade and histotype.61,62,72,73 Anthracyclines with or without ifosfamide 
remain the frontline systemic therapy for most histotypes in both paediatric and adult patients, 
with some evidence of a dose response for both agents and better activity for the combination 
therapy versus single-agent doxorubicin.72,73 Phase 3 results are awaited to confirm the 
remarkable gain in overall survival of almost 1 year with the combination of doxorubicin and 
the PDGFRα antibody olaratumab versus single-agent doxorubicin.74 However, various drugs 
other than the ifosfamide–doxorubicin combination are also effective against particular 
histotypes in adults: for example, the gemcitabine–docetaxel regimen is considered second-
line chemotherapy in the USA, with better activity in angiosarcomas and leiomyosarcomas 
(particularly those of gynaecological origin).75 Trabectedin has been approved in Europe for 
relapsed or refractory adult soft tissue sarcomas, with specific activity against liposarcomas 
and leiomyosarcomas, and has been approved in the USA for second-line treatment of 
liposarcomas and leiomyosarcomas.76–78 Eribulin has shown an overall survival benefit in 
unresectable and metastatic liposarcoma.79 Ongoing research is focusing on new histology-
driven therapeutic approaches, and future clinical trials are likely to concentrate on specific 
histology-based accrual rather than accrual of patients with heterogeneous soft tissue sarcoma 
histologies. 
In patients with localised disease, the possible role of adjuvant chemotherapy in the prevention 
of distant recurrences after initial surgery is still a matter of controversy and, despite initially 
promising results in high-risk extremity soft tissue sarcomas, final results showing improved 
survival in the long term have not been published.55,80–82 Pooled data from adjuvant studies by 
the European Organisation for Research and Treatment of Cancer (EORTC) suggest a potential 
benefit of adjuvant treatment in R2 resected extremity tumours, but a prospective clinical trial 
is required before this observation can be used to influence clinical practice.55 Thus, the choice 
of whether or not to administer adjuvant chemotherapy can only be based on shared and 
personalised decision making, for those patients who are at high risk of metastatic disease and 
for those patients whose tumours have histological characteristics that make them more likely 
than others to respond to chemotherapy. 
Hopefully, identification of more druggable targets and development of more active small 
molecules and antibodies will increase options for effective treatment in the metastatic and 
adjuvant (and neoadjuvant) settings. Several tyrosine kinase inhibitors have shown activity in 
various histotypes of soft tissue sarcoma, including imatinib in dermatofibrosarcoma 
protuberans, sunitinib and cediranib in alveolar soft-part sarcoma, VEGF receptor inhibitors in 
solitary fibrous tumours and desmoplastic small round cell tumours, the mTOR inhibitor 
sirolimus in perivascular epithelioid cell tumours, and the anaplastic lymphoma kinase (ALK) 
inhibitor crizotinib in inflammatory myofibroblastic tumours.83 Pazopanib—a multitargeted 
receptor tyrosine kinase inhibitor—has been approved for the treatment of refractory soft tissue 
sarcomas after a phase 3 randomised trial of pazopanib versus placebo in advanced or 
metastatic soft tissue sarcomas (excluding liposarcomas) showed an improvement in median 
progression-free survival (4·6 months vs 1·6 months; HR 0·31; 95% CI 0·24–0·40; 
p<0·0001).84 
Clinical trials of new agents are often restricted in paediatric and adolescent populations. 
Therapeutic results seen in adult patients need to be confirmed in paediatric patients, but 
confirmatory studies are not yet done sufficiently. Physicians dealing with adolescents should 
determine whether the results observed in adults can be translated to paediatric patients, and 
whether a given soft tissue subtype has the same biological and clinical characteristics in 
different age groups. Effective progress in the treatment of adolescents can only be achieved 
through new forms of collaboration, including close cooperation between adult and paediatric 
oncologists to share experiences and skills, collaboration with biologists to identify relevant 
targets and pathways relevant to tumour growth and, where possible, to adjust the therapy on 
the basis of tumour biology, and broad networking with pharmaceutical industries and 
regulatory authorities to speed up the whole process. 
 
Models of care and organisation of paediatric and adult 
oncology trials in Europe 
For bone sarcoma, many examples exist of good collaboration between countries and between 
different groups of oncologists. The European Osteosarcoma Intergroup has existed for 
decades, and the globally executed EURAMOS study (NCT00134030) is a great example of 
collaboration between paediatric and adult oncologists.85,86 Similarly, the Euro-Ewing99, Euro-
Ewing2012 (ISRCTN 92192408), and rEECurr (ISRCTN 36453794) studies are also being 
done by representatives of both professional specialties.87 However, collaborative efforts and 
international networks between paediatric and adult oncologists for soft tissue sarcomas are 
not as well developed as those for bone sarcomas. 
For example, the EpSSG has only done studies in children. Even the most recently developed 
rhabdomyosarcoma study, the FaR-RMS study, has been created by paediatricians only, albeit 
with the inclusion of patients without upper age limits. Meanwhile, the EORTC Soft Tissue 
and Bone Sarcoma Group has always developed protocols for adults only. The EORTC's 
CREATE trial, which uses crizotinib (ClinicalTrials.gov number: NCT01524926), has now 
included subgroups of soft tissue sarcomas also occurring in paediatric patients, and has thus 
included paediatricians in its investigations. To allow the progress of new trials in the era of 
targeted therapies and novel immunological strategies, a collaborative effort between 
paediatric oncologists and adult oncologists is clearly needed from the outset. These 
collaborations should also include pathologists, molecular biologists, and professionals with 
expertise in psychosocial issues that could interfere with active treatment and have an impact 
on late effects in adolescent and young adult patients with sarcomas.88 
Paediatric and adult oncologists have launched the EuroJOSS initiative for the development of 
joint studies in synovial sarcoma. This collaboration is new and still faces many challenges, 
but benefits from a strong pan-European support network. Such collaborations should not, 
however, be limited to the most common adolescent and young adult sarcomas but should also 
address rare histotypes, such as epithelioid sarcomas, desmoplastic small round cell tumours, 
clear cell sarcomas, and alveolar soft part sarcomas. 
A global multicentre study89 focusing on hereditary genetic factors has revealed that patients 
with sarcoma might have specific genetic aberrations that could affect screening and eventually 
affect their response to novel therapeutic strategies. These genetic factors are likely to have a 
greater role for younger patients. International, collaborative research is needed to address the 
many unanswered questions on this important topic. 
Apart from treatment protocols, it is important to create an environment for young adults and 
adolescents with sarcoma that is tailored to their own personal lives. Therefore, dedicated 
multidisciplinary teams for these young, but not paediatric, patients are considered to be 
increasingly important, as these patients encounter their own age-specific issues such as 
changed body image (due to major surgical procedures, radiotherapy, or chemotherapy), 
fertility, sexual and other relationships, education, employment (often first jobs), housing, 
independent living, psychosocial age-related issues, and so on.88 The importance of addressing 
these aspects is now recognised, since these efforts could contribute to an improved adherence 
to treatment and improved patient experience. As the treatment strategies for sarcomas often 
entail intensive treatment schedules and lasting late effects, adolescents and young adults with 
soft tissue sarcomas would clearly benefit from programmes tailored to their age-specific 
needs, especially when integrated with sarcoma expert teams and incorporated into national 
and even international networks.90 
 
Conclusion 
Soft tissue sarcomas are rare in adolescents and young adults, and improving survival has been 
challenging in the past few decades because of treatment-related and age-related factors. 
Sarcomas in this age group encompass the tail end of predominantly paediatric sarcomas (such 
as embryonal and alveolar rhabdomyosarcomas), sarcomas specifically related to young 
patients with cancer (such as Ewing's sarcoma, osteosarcoma, and synovial sarcoma), and the 
first adult sarcomas occurring at an unusually young age. Hereditary genetic factors might be 
involved in certain sarcomas to a greater extent than previously thought, which could have 
consequences for family counselling and might lead to new treatment paradigms. 
Differences in outcomes between children and young adults with the same histological sarcoma 
diagnoses are partly due to tumour-associated factors, as best exemplified in synovial sarcoma, 
and partly due to differences in treatment. Inadequate access to centres of expertise and to new 
clinical trials have contributed substantially to the slow progress in improving outcomes. To 
address this problem, increased collaboration at both the national and international level is 
needed between experts from solid paediatric oncology and the adult sarcoma specialties. 
Given the rarity of these tumours and the effort involved in initiating and running clinical trials 
in these indications, centralisation of care and research in each country is needed for this age 
group. Ideally, care should be delivered by teams that include experts on adolescent and young 
adult oncology to address the age-specific needs of these patients. 
Moreover, at an international level, medical specialists from paediatric and adult oncology 
disciplines should take responsibility for the development and initiation of new clinical trials. 
Funding of such trials remains challenging, which can delay new initiatives. A new approach 
towards global funding, with support from different sources, including the pharmaceutical 
industry, charities, and funding organisations, is needed to start and grow these initiatives. 
Digital methods of communication should be further explored to develop a more 
interconnected international community, with the aim of improving outcomes of adolescent 
and young adult patients with sarcoma. 
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Table 1: Age-related studies of patients with synovial sarcoma with localised disease at 
diagnosis 
 
HR=hazard ratio. NR=not reported. * p value based on the multivariate analysis. 
Figure 1. Distribution of the CINSARC, genomic index, and metastasis-free survival in 
paediatric and adult patients with synovial sarcoma. An example of two CGH profiles in 
children and adults with synovial sarcoma. In this analysis, paediatric patients with synovial 
sarcoma have more favourable biological tumour features than do adults, a lower somatic 
tumour complexity index, lower genomic index signatures, and less metastatic tumour 
evolution. Data adapted from Lagarde and colleagues.20 CGH=comparative genomic 
hybridisation. CINSARC=a somatic tumour complexity index in sarcoma signatures. C+=high 
CINSARC. C–=low CINSARC. GI+=high genomic index. GI–=low genomic index. 
M+=metastatic event. M–=absence of metastatic event. 
 
